Since the first oligonucleotide (OGNT) drug was approved by the FDA for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology, and development methods. However, due to the complexity and sensitivity of OGNTs, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.
Join oligonucleotide bioanalysis SME Troy Voelker, Director of Laboratory Operations at Aliri, as he discusses:
- Current and future state of the bioanalysis of OGNTs
- Common approaches to bioanalysis of OGNTs
- Evaluating and selecting the optimal and strategic approach